Grants to treat alcohol use disorder and transform cancer diagnosis

Sydney researchers have received two National Health and Medical Research Council (NHMRC) Synergy Grants worth $10 million.

Two University of Sydney research teams have been awarded NHMRC Synergy Grants to lead projects that will develop treatments for alcohol use disorder and transform diagnosis of breast and lung cancer.

The Synergy Grants, announced today by the Hon. Greg Hunt MP, support outstanding multidisciplinary teams of investigators to work together to answer major questions that cannot be answered by a single investigator.

Professor Robyn Ward, Executive Dean of the Faculty of Medicine and Health, congratulated the researchers.

“The success in securing two synergy grants speaks to the innovative and collaborative nature of the projects.

“Both teams are tackling significant health problems, with the focus on improving long-term outcomes for patients and their families.”

Linking clinical and basic science discovery to find new treatments for alcohol use disorder

Professor Paul Haber and Associate Professor Kirsten Morley from the Faculty of Medicine and Health are chief investigators on a project which will deliver new approaches to treat alcohol use disorder, including how to tailor treatment to individual patient characteristics.

“More than a million Australians meet criteria for an alcohol use disorder, making it a leading cause of injury, chronic disease and mortality,” said Professor Haber.

“During the COVID-19 pandemic we’ve also seen increased consumption of alcohol and hospital admissions from alcohol problems.

“Current treatment options have limited effectiveness and there haven’t been any new medication discoveries for 20 years.”

“This program will allow us to improve the treatment options for this common and disabling disorder by building a large collaborative research network to bridge the gaps between discovery sciences and the clinic,” said Associate Professor Morley.

“We will identify mechanisms and predictors of efficacy to inform future drug discovery and develop a personalised medicine approach that will improve the lives of many Australians.”

Prof Paul Haber University of Sydney
Assoc Prof Kirsten Morley University of Sydney
Prof Andrew Lawrence Florey Institute of Neuroscience and Mental Health
Assoc Prof Victoria Manning Monash University
Prof Daniel Lubman Monash University
Prof Gavan McNally University of New South Wales
Dr Zayra Millan University of New South Wales
Dr Shalini Arunogiri Monash University
Prof Antonio Verdejo-Garcia Monash University
Dr Leigh Walker Florey Institute of Neuroscience and Mental Health
Dr Warren Logge Sydney Local Health District
Dr Rowan Ogeil Monash University
Prof Lorenzo Leggio National Institute of Health
Prof Henry Kranzler University of Pennsylvania
Prof Andrew Baillie University of Sydney
Prof Ronald Grunstein University of Sydney
Dr Christina Perry Macquarie University
Assoc Prof Yvonne Bonomo St Vincent’s Hospital Melbourne

IMPACT: IMplementation of x-ray PhAse-Contrast Tomography to transform cancer diagnosis

Professor Patrick Brennan, Professor Sarah Lewis and Dr Amir Tavakoli Taba from the Faculty of Medicine and Health are chief investigators on a program that will transform diagnosis of breast and lung cancer by establishing a path to clinical implementation of a novel low-dose, high-quality, 3D imaging technique.

“Propagation-based phase-contrast computed tomography (PB-CT) can improve the imaging signal 10-fold, leading to a considerable improvement in image quality and a substantial reduction in the X-ray dose, compared to conventional X-ray imaging techniques,” said Professor Brennan.

“Successful clinical translation of PB-CT requires a multidisciplinary team of experts in academia and beyond. This Synergy Grant allows us to bring together the right people to deliver a world-first PB-CT imaging facility.

“The program could revolutionise breast and lung cancer diagnosis worldwide and position Australia as an international hub of scientific, clinical and industrial excellence in X-ray phase-contrast imaging.

“Through vastly improved cancer diagnosis and reduced risk and discomfort, PB-CT has the potential to significantly reduce cancer mortality and morbidity.”

Prof Patrick Brennan University of Sydney
Prof Harry Quiney University of Melbourne
Prof Sarah Lewis University of Sydney
Prof Keith Nugent Australian National University
Prof Andrew Peele Australian Nuclear Science and Technology Organisation
Dr Seyedamir Tavakoli Taba University of Sydney
Dr Kaye Morgan Monash University
Ms Jane Fox Monash Health
Mrs Giuliana Tromba Elettra Sincrotrone Trieste
Dr Darren Lockie Eastern Health
Dr Timur Gureyev University of Melbourne
Dr Yakov Nesterets CSIRO Manufacturing Flagship
Dr Christian Dullin University Medical Center Gottingen
Dr Daniel Hausermann Australian Synchrotron
Dr Sheridan Mayo CSIRO Manufacturing Flagship
Dr Matthew Dimmock Monash University

/University Release. This material from the originating organization/author(s) may be of a point-in-time nature, edited for clarity, style and length. The views and opinions expressed are those of the author(s).View in full here.